News Blow for AstraZeneca as cancer combination fails After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy.
News AZ CEO set to take charge at Teva - report Report raises concerns about outcome of MYSTIC trial.
News UK ministers seek a soft Brexit for pharma Health and business secretaries commit to close working with EMA
News AZ sells migraine drug rights to Grunenthal for $300m AZ says migraine outside its strategic focus.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.